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Abstract
The adoptive transfer of antigen-specific CD8+ T cells is a promising approach for the treat-
ment of chronic viral and malignant diseases. In order to improve adoptive T cell therapy
(ATT) of cancer, recent strategies aim at the antibody-based blockade of immunosuppres-
sive signaling pathways in CD8+ T cells. Alternatively, adjuvant effects of immunostimula-
tory cytokines might be exploited to improve therapeutic CD8+ T cell responses. For
example, Interleukin-7 (IL-7) is a potent growth, activation and survival factor for CD8+ T
cells that can be used to improve virus- and tumor-specific CD8+ T cell responses. Although
direct IL-7 effects on CD8+ T cells were studied extensively in numerous models, the contri-
bution of IL-7 receptor-competent (IL-7R+) host cells remained unclear. In the current study
we provide evidence that CD8+ T cell-mediated tumor rejection in response to recombinant
IL-7 (rIL-7) therapy is strictly dependent on IL-7R+ host cells. On the contrary, CD8+ T cell
expansion is independent of host IL-7R expression. If, however, rIL-7 therapy and peptide
vaccination are combined, host IL-7R signaling is crucial for CD8+ T cell expansion. Unex-
pectedly, maximum CD8+ T cell expansion relies mainly on IL-7R signaling in non-hemato-
poietic host cells, similar to the massive accumulation of dendritic cells and granulocytes. In
summary, we provide evidence that IL-7R+ host cells are major targets of rIL-7 that modu-
late therapeutic CD8+ T cell responses and the outcome of rIL-7-assisted ATT. This knowl-
edge may have important implications for the design and optimization of clinical ATT
protocols.
Introduction
The size of the peripheral T cell pool is remarkably stable throughout life. Although infections
can cause a strong increase in T cell numbers, they usually return to steady-state levels after
pathogen clearance. This indicates that self-regulatory mechanisms maintain T cell numbers
[1]. A central factor controlling peripheral T cell homeostasis is IL-7. It acts as a growth and
survival signal for T cells, which express the IL-7R and constitutively consume IL-7 [2]. Conse-
quently, the size of the peripheral T cell pool becomes self-limiting as soon as IL-7 production
PLOSONE | DOI:10.1371/journal.pone.0159690 July 22, 2016 1 / 17
a11111
OPEN ACCESS
Citation: Deiser K, Stoycheva D, Bank U,
Blankenstein T, Schüler T (2016) Interleukin-7
Modulates Anti-Tumor CD8+ T Cell Responses via Its
Action on Host Cells. PLoS ONE 11(7): e0159690.
doi:10.1371/journal.pone.0159690
Editor: Xue-feng Bai, Ohio State University, UNITED
STATES
Received: March 21, 2016
Accepted: July 5, 2016
Published: July 22, 2016
Copyright: © 2016 Deiser et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by the Deutsche
Forschungsgemeinschaft (grants SFB-TR36 (B7) and
SFB854 (A22) to TS). The funder had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
and consumption reach an equilibrium [1]. Due to the lack of IL-7 consumption by T cells, IL-
7 availability is increased in lymphopenic humans [3] and mice [4]. Lymphopenia-associated
IL-7 overabundance contributes to the activation of naïve T cells, which undergo homeostatic
or lymphopenia-induced proliferation (LIP) and convert into memory-like cells, which express
high levels of CD44 and IFNγ [5].
The adoptive transfer of antigen-specific T cells is an important therapeutic option for the
treatment of viral infections and cancer and has been performed successfully in animal models
as well as in the clinic [6,7]. It is well established that the efficacy of adoptive T cell therapy
(ATT) can be improved if recipient T cells are depleted by chemotherapy or irradiation prior
to T cell transfer [6,8]. This positive effect of lymphodepletion results from the increased avail-
ability of T cell growth and survival factors such as IL-7 [9,10].
From our own experiments we know that thymus, lymph nodes, skin and intestine are the
major sources of IL-7 in the mouse [11,12]. Nevertheless, steady-state IL-7 production is not
sufficient for effective anti-tumor T cell responses under non-lymphopenic conditions. The
injection of recombinant IL-7 (rIL-7) circumvents this problem and boosts anti-tumor T cell
responses [13,14]. Since IL-7 promotes T cell survival [15,16], activation [17,18], proliferation
[19] and memory T cell (TM) formation [20] its direct action on T cells is supposed to be the
major cause for its potent anti-tumor effects [21]. For the effective treatment of viral infections
and cancer by ATT high numbers of adoptively transferred CD8+ cells are required in vivo [7].
Their longevity and subsequent accumulation can be improved by rIL-7 therapy suggesting
that this approach can be used to improve ATT [21]. Importantly, the adjuvant effects of rIL-7
correlate with tumor growth delay rather than complete rejection [13,22,23]. Given that i) reg-
ulatory immune cells such as dendritic cells (DCs) and granulocytes expand in response to ele-
vated IL-7 levels [24,25] and ii) non-hematopoietic cells such as fibroblasts and intestinal
epithelial cells express functional IL-7 receptors (IL-7R) [12,26], we hypothesized that IL-7R+
host cells might modulate anti-tumor CD8+ T cell responses.
In the current study we asked whether and how host IL-7R signaling affects ATT efficacy.
For this purpose we established an ATT model, which enabled us to discriminate between
direct and indirect effects of rIL-7 therapy on tumor-specific CD8+ T cells. Our data demon-
strate, that LIP of CD8+ T cells and subsequent TM differentiation are promoted by rIL-7 in a
host IL-7R-independent manner. However, tumor rejection strictly requires host IL-7R expres-
sion. Furthermore, we show that IL-7R+ non-hematopoietic host cells are crucial for maximum
CD8+ T cell expansion and TM differentiation if rIL-7 therapy is combined with peptide vacci-
nation. Importantly, despite efficient CD8+ T cells expansion, peptide vaccination deteriorates
rIL-7-dependent ATT efficacy. In summary, we provide evidence that host IL-7R signaling
modulates multiple aspects of CD8+ T cells activation and TM differentiation and can promote
tumor rejection in a context-dependent fashion.
Materials and Methods
Mice
C57BL/6J (WT), B6.PL-Thy1a/Cy (CD90.1+), B6.SJL-Ptprca Pepcb/BoyJ (CD45.1+),
B6.129S7-Rag1tm1Mom/J (Rag-/-), B6.129S7-Il7rtm1Imx/J (IL-7R-/-), C57BL/6-Tg(TcraTcrb)
1100Mjb/J (OT-I) (expressing a transgenic TCR specific for the chicken ovalbumin (OVA)-
derived, H2-Kb–restricted peptide OVA257-264 (SIINFEKL)), IL-7GCDL [11] and ChRluc mice
[27] were bred in our animal facilities. All mice were housed under specific pathogen-free con-
ditions. Animal experiments were performed according to institutional guidelines and were
approved by the Landesamt für Gesundheit und Soziales Berlin (Permit Number: G0170/08)
and Landesverwaltungsamt Sachsen-Anhalt (Permit Number: 2–1155 Uni MD).
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Generation of bone marrow (BM) chimeras and bioluminescence
detection
BM recipients were anesthetized (Ketamin/Rompun i.p.), irradiated lethally and injected with
BM cells i.v. 6–18 hours later. Donor BM was isolated from femur and tibia. BM from one
donor was used to reconstitute 3 recipients. BM chimeras received antibiotics via the drinking
water for 3–4 weeks and were used for experiments earliest 6 weeks after BM injection. To visu-
alize luciferase activity in live animals, bioluminescence intensities (BLI) were measured using
the IVIS Imaging system (Xenogen) as described before [11,27].
Adoptive T cell transfer, peptide vaccination and IL-7 treatment
Naïve CD8+ T cells were purified from spleen and lymph nodes of the respective donor mice
using CD8α-specific microbeads and AutoMACS (Miltenyi Biotec). 7 x 105–1 x 106 CD8+ T cells
(purity>97%) were injected i.v. into the tail vein of recipient mice. For peptide vaccination,
50 μg of SIINFEKL were injected i.v. one day after T cell transfer. Control animals were injected
with Dulbecco’s PBS. Prior to injection, recombinant murine IL-7 (rIL-7) (eBioscience) and anti-
IL-7 mAb (M25; BioXCell) were mixed and incubated for 20 min at RT. Unless otherwise stated,
200 μl of 1,5 μg rIL-7 and 10 μg anti-IL-7 mAb in PBS were injected i.p every 3–4 days starting
one day prior to T cell transfer.
Tumor cell challenge
EG7 lymphoma cells produce chicken ovalbumin (OVA) and are targets of CD8+ OT-I T cells.
EG7 cells were cultured in RPMI+10% FCS medium with 0.4 mg/ml G418. 1 x 106 cells were
injected s.c. in the right flank of the indicated mice. Mice with tumors>250 mm3 were scored
as tumor positive. Tumor growth was monitored every 2–3 days. Mice were euthanized by cer-
vical dislocation when tumors reached a diameter of 10–15 mm or when showing the following
signs: hunched posture, inactivity, worsening body condition, rough coat, orbital tightening or
abnormal breathing. Body weight was not assessed in this study.
Flow cytometry
The following antibodies were used: anti-CD8α (53–6.7; eBioscience/Biolegend/BD), -CD90.1
(OX-7; Biolegend/BD), -CD62L (MEL-14; Biolegend/BD), -CD44 (IM7; eBioscience/Biole-
gend/BD), -KLRG-1 (2F1; eBioscience), PD-1 (J43; eBioscience), -Ki67 (SolA15; eBioscience),
CD127 (A7R34; BD/Biolegend), CD132 (TUGm2; BD), -Bcl-2 (10C4; Biolegend), -IFN-γ
(XMG1.2; Biolegend/eBioscience), -TNF-α (MP6-XT22; BD), -CD11c (N418; BD/Biolegend),
-CD11b (MI70; BD/Biologend), Gr-1 (RB6-8-C5; Biolegend). Stimulation of CD8+ OT-I T
cells with SIINFEKL and subsequent intracellular cytokine staining was performed as described
recently [28]. Samples were measured on FACSCalibur, FACSCanto or LSRII flow cytometers
and analyzed by FlowJo software (FlowJo, LLC).
Statistical analysis
Statistical analysis and graphical representations were done using Prism5 software (GraphPad
Software). Statistical significance was determined using a non-parametric two-tailed Mann-
Whitney, paired Student’s t, 1- and 2-way Anova, log-rank or Wilcoxon matched-pairs signed
rank test.  p<0,05;  p<0,01;  p<0,001.
IL-7 Therapy and Host Cells
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Results
Host IL-7R signaling is crucial for rIL-7-dependent, CD8+ T cell-mediated
tumor rejection
Naïve CD8+ T cells transferred into lymphopenic mice undergo lymphopenia-induced prolif-
eration (LIP), differentiate into CD44hi memory-like T cells [5] and limit tumor growth [8].
Accordingly, naive CD8+ TCR-transgenic (tg) OT-I T cells specific for the chicken ovalbumin
(OVA)-derived, H2-Kb-restricted peptide SIINFEKL, expanded and up regulated CD44 in
lymphopenic Rag1-deficient (Rag-/-) recipients within 21–27 days after transfer. Expansion
and TM differentiation were not observed in OT-I-reconstituted, non-lymphopenic wildtype
(WT) mice (S1 Fig). Whether LIP-associated CD8+ T cell activation leads to tumor growth
inhibition was tested next. Twenty-two days after reconstitution with naive CD8+ OT-I T cells,
Rag-/- mice were challenged s.c. with 106 OVA-expressing EG7 lymphoma cells. EG7 tumors
grew rapidly in untreated Rag-/- mice while adoptive T cell transfer strongly delayed tumor
growth (Fig 1A). Nevertheless, only 1 mouse out of 11 remained long-term tumor-free.
In order to investigate whether IL-7 therapy promotes tumor rejection, groups of OT-I-
reconstituted Rag-/- mice received rIL-7 every 3–4 days for 18 days starting one day prior to
adoptive T cell transfer. To improve its function, rIL-7 was complexed with IL-7-specific anti-
bodies (αIL-7) prior to injection as described before [29]. 7/12 Rag-/- mice receiving OT-I T
cells plus IL-7 therapy completely rejected EG7 lymphoma cells demonstrating that IL-7 ther-
apy strongly enhances OT-I-dependent tumor rejection in our experimental system (Fig 1A).
Importantly, rIL-7 treatment did not affect primary EG7 growth in either host (data not
shown).
Fig 1. Host IL-7R signaling is required for CD8+ T cell-mediated tumor rejection in response to IL-7
treatment. (A-C) Rag-/- and Rag-/-IL-7R-/- mice were reconstituted with 7–10 x 105 CD8+CD90.1+ OT-I T cells
or were left untreated (+/- OT-I). OT-I-reconstituted mice received rIL-7 (+ IL-7) or PBS (- IL-7) every 3–4 days
for 18 days starting one day before T cell transfer. (A, B) 22–23 days after T cell transfer, some mice were
challenged s.c. with 1 x 106 ovalbumin-expressing EG7 lymphoma cells. Mice with tumors >250 mm3 were
scored as tumor positive. Pooled data from 2 independent experiments with a total of 10–12 mice per group
are shown. Statistical significance was calculated using the log-rank test. (C, D) Some recipients were not
challenged with EG7 but analyzed for OT-I expansion and phenotype. (C) Splenic CD8+CD90.1+ OT-I T cells
were quantified 21–25 days after adoptive transfer. Pooled data (±SEM) from 2 independent experiments
with a total of 7–9 mice/group are shown. (D) CD127 expression of splenic OT-I T cells was determined 5
days after adoptive transfer. Data (±SEM) for 3–4 mice/group are shown.
doi:10.1371/journal.pone.0159690.g001
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Several studies provided evidence that rIL-7 promotes activation, survival, function of CD8+
T cells [15–19,30] and memory T cell (TM) formation [20]. So far, however, these effects were
considered to result from direct effects of rIL-7 on CD8+ T cells. Besides CD8+ T cells, however,
numerous hematopoietic and non-hematopoietic cells express the IL-7 receptor (IL-7R) [31].
Hence, it remained unclear whether the success of IL-7-assisted adoptive T cell transfers relies
on IL-7R signaling in CD8+ T cells and/or host cells. In order to address this question, Rag-/-
mice lacking the IL-7Rα chain (Rag-/-IL-7R-/-) were reconstituted with OT-I T cells, received
IL-7 therapy or PBS and were challenged with EG7 lymphoma cells. This approach allowed us
to separate direct from indirect effects of rIL-7 on CD8+ T cell-mediated lymphoma rejection.
As compared to untreated controls, OT-I cells strongly delayed tumor growth in Rag-/-IL-7R-/-
recipients (Fig 1B) similar to what we had observed in Rag-/- mice (Fig 1A). This demonstrates
that host IL-7R-deficiency does not limit LIP-associated CD8+ TM differentiation (S1 Fig) and
subsequent anti-tumor immunity (Fig 1B). In contrast to Rag-/- mice, rIL-7 treatment of OT-I-
reconstituted Rag-/-IL-7R-/- mice did not improve anti-tumor CD8+ T cell responses (Fig 1B)
indicating that direct effects of rIL-7 on CD8+ T cells are not sufficient for successful tumor
rejection. In fact, IL-7R signaling by host cells is crucial for tumor rejection after CD8+ T cell
transfer and rIL-7 therapy. Next we studied whether impaired tumor rejection in Rag-/-IL-7R-/-
mice resulted from reduced LIP. Rag-/- and Rag-/-IL-7R-/- mice were reconstituted with CD8+
OT-I T cells and spleen cells were analyzed 21–27 days later. CD44 levels (S1A Fig) and recov-
ery rates (S1B Fig) did not differ between OT-I cells from Rag-/- and Rag-/-IL-7R-/- mice. In
conclusion, LIP-driven expansion and TM formation are independent of host IL-7R signaling.
To analyze the impact of host IL-7R signaling on rIL-7 therapy-related TM differentiation
and expansion, Rag-/- and Rag-/-IL-7R-/- mice were reconstituted with OT-I T cells and treated
with rIL-7 (+IL-7) or PBS (-IL-7) as described above. In accordance with S1B Fig, similar num-
bers of OT-I cells were recovered from spleens of PBS-treated Rag-/- and Rag-/-IL-7R-/- mice
21–25 days after adoptive transfer (Fig 1C). IL-7 signaling suppresses IL-7Rα chain (CD127)
expression by naive T cells [32]. Accordingly, a strong and host-independent down-modula-
tion of CD127 was observed 5 days after adoptive transfer and rIL-7 treatment (Fig 1D).
Importantly, OT-I T cells expressed less CD127 in PBS-treated Rag-/-IL-7R-/- than in Rag-/-
mice arguing for elevated steady state IL-7 levels in the latter. Nevertheless, this did not affect
the long-term abundance (Fig 1C) or early rIL-7 responsiveness of OT-I T cells (Fig 1D).
In conclusion, host IL-7R signaling is dispensable for rIL-7-driven CD8+ T cell expansion
(Fig 1C) but not for subsequent tumor rejection. This highlights that high numbers of thera-
peutic CD8+ T cells do not necessarily correlate with therapeutic success.
Host IL-7R signaling is not required for rIL-7-induced TM differentiation
but for granulocyte and DC expansion
CD8+ TM express high levels of CD127 and the anti-apoptotic molecule B cell lymphoma pro-
tein-2 (Bcl-2) [33], which can be up regulated by IL-7 [34]. In PBS-treated Rag-/- mice CD127hi
and Bcl-2hi OT-I TM were less frequent than in Rag
-/-IL-7R-/- mice (Fig 2A and 2B). In
response to rIL-7 treatment, however, resulting OT-I TM expressed elevated levels of CD127
and Bcl-2 in both hosts 21–25 days after transfer (Fig 2A and 2B). Hence, despite early CD127
down-regulation (Fig 1D), IL-7 therapy promoted the generation of CD127hiBcl-2hi OT-I TM
irrespective of the host. IL-7 therapy also promoted the generation of CD62Lhi OT-I cells (Fig
2C) expressing low levels of KLRG-1 (Fig 2D). Furthermore, a high percentage of OT-I cells
recovered from both hosts rapidly produced IFN-γ after short-term in vitro re-stimulation
(Fig 2E). Hence, rIL-7 therapy favors the generation of functional CD8+ TM cells with a
CD127hiBcl-2hiCD62LhiKLRG-1lo phenotype in a host-independent fashion. Interestingly,
IL-7 Therapy and Host Cells
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despite their high numbers (Fig 1C) and favorable phenotype (Fig 2), rIL-7-induced OT-I TM
cells failed to reject tumors in Rag-/-IL-7R-/- mice (Fig 1B). This suggested a contribution of
rIL-7-responsive host cells to EG7 elimination.
After rIL-7 treatment, spleen cell numbers increased dramatically in Rag-/- mice (Fig 3A). In
agreement with previous studies [24,25], CD11b+Gr-1+ granulocytes and CD11c+MHCII+
DCs expanded most efficiently in response to rIL-7 (Fig 3B and 3C). Among the latter, CD8+
lymphoid and CD8- myeloid DCs responded similarly well (Fig 3D and 3E). In Rag-/-IL-7R-/-
mice rIL-7 therapy failed to induce the expansion of splenocytes, granulocytes and DCs (Fig
3A–3E) excluding IL-7R-independent side effects of our treatment regimen. In summary, host
IL-7R signaling is crucial for rIL-7-induced, CD8+ T cell-mediated tumor rejection (Fig 1A and
1B), is not essential for CD8+ TM differentiation (Fig 2) but promotes the expansion of granulo-
cytes and DCs.
Host IL-7R signaling promotes CD8+ T cell expansion and modulates TM
differentiation in response to peptide vaccination and IL-7 therapy
IL-7 administration improves vaccination-induced T cell responses [13,22]. To test whether
this also requires host IL-7R signaling, Rag-/- and Rag-/-IL-7R-/- mice were reconstituted with
OT-I cells, immunized with SIINFEKL and treated with rIL-7. Peptide-vaccinated mice receiv-
ing PBS served as controls. As shown in Fig 4A rIL-7 treatment strongly increased spleen cell
numbers in Rag-/- but not Rag-/-IL-7R-/- mice. Furthermore, rIL-7 treatment promoted OT-I
Fig 2. Host IL-7R signaling is not required for rIL-7-induced TM differentiation. (A-E) Rag
-/- and Rag-/-IL-
7R-/- mice were treated with rIL-7 or PBS (+/- IL-7) every 3–4 days starting one day prior to adoptive transfer
of 1 x 106 CD8+CD90.1+ OT-I T cells. 21–25 days after transfer, splenic OT-I T cells were analyzed by flow
cytometry. After gating on CD8+CD90.1+ or CD8+Vα2+ OT-I T cells, mean fluorescence intensities (MFIs) for
(A) CD127 and (B) Bcl-2 as well as the frequencies (frequ.) of (C) CD62Lhi, (D) KLRG-1hi and (E) IFN-γhi cells
were determined. IFN-γ production was measured after in vitro re-stimulation with 1 μMSIINFEKL peptide in
the presence of brefeldin A for 6 hours. (A-E) Data shown in bar diagrams were normalized to the mean
values determined in PBS-treated Rag-/- mice and are shown as relative (rel.) values. Pooled data (±SEM)
from 2–3 independent experiments with a total of 7–13 mice/group are shown. Histogram overlays show
relative cell numbers (rel. cell #) and relative fluorescence intensities (rel. fl. int.) for individual mice after
gating on OT-I cells. Dashed lines in overlays represent (A-D) FMO control samples or (E) stained cells
without prior SIINFEKL stimulation.
doi:10.1371/journal.pone.0159690.g002
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cell expansion in Rag-/- mice (Fig 4B). Although to a much lesser extent, this was also observed
in rIL-7-treated Rag-/-IL-7R-/- mice (Fig 4B). Thus, IL-7R signaling in CD8+ T cells promotes
some degree of rIL-7-induced CD8+ T cell expansion although the full-blown response requires
host IL-7R expression.
To test whether IL-7R+ host cells also modulate TM differentiation the phenotype of
peripheral blood OT-I cells was determined by flow cytometry. In Rag-/- and Rag-/-IL-7R-/-
mice, frequencies of CD62Lhi OT-I cells were similar after vaccination (Fig 4C). This was fur-
ther increased by rIL-7 and was independent of host IL-7R expression (Fig 4C). OT-I cells
expressed similar levels of CD127 after vaccination of Rag-/- and Rag-/-IL-7R-/- mice. To our
surprise, rIL-7 therapy further promoted CD127 expression by OT-I cells only in Rag-/- mice
(Fig 4D). KLRG-1hi OT-I cells were more frequent in vaccinated Rag-/-IL-7R-/- than in Rag-/-
mice. In both hosts their abundance decreased in response to rIL-7, though to a lesser extent in
Rag-/-IL-7R-/- mice (Fig 4E). After vaccination, OT-I proliferation was lower in Rag-/- mice as
shown by low numbers of Ki67hi cells (Fig 4F). Bcl-2 expression was similar in vaccinated
Rag-/- and Rag-/-IL-7R-/- mice and was up regulated by rIL-7 only in the latter (Fig 4G). In sum-
mary, the rIL-7-induced up-regulation of CD62L by OT-I cells was largely independent of IL-
7R+ host cells. In contrast, host cells promoted the expansion of OT-I cells (Fig 4B) and modu-
lated their expression of CD127, KLRG-1 and Bcl-2 in response to rIL-7 therapy (Fig 4D, 4E
and 4G).
After vaccination, OT-I cells isolated from Rag-/- mice produced high levels of IFN-γ (Fig
4H). This response was less pronounced in Rag-/-IL-7R-/- mice but could be improved by rIL-7
treatment (Fig 4H). Importantly, rIL-7 treatment could not further promote the generation of
IFN-γhi OT-I cells in Rag-/- mice (Fig 4H). OT-I cells producing high levels of TNF-α were sim-
ilarly frequent in Rag-/- and Rag-/-IL-7R-/- mice and further expanded in both hosts in response
to rIL-7 treatment (Fig 4I). The expression of PD-1, a marker for dysfunctional T cells, was
comparable for OT-I cells recovered from mice of both strains. In agreement with a previous
study [35], rIL-7 administration reduced PD-1 expression on OT-I cells in Rag-/- mice (Fig 4J).
Surprisingly, this was not the case in Rag-/-IL-7R-/- mice (Fig 4J) indicating that IL-7R+ host
Fig 3. Host IL-7R signaling is required for granulocyte and DC expansion in response to rIL-7. Rag-/-
and Rag-/-IL-7R-/- mice were treated with rIL-7 or PBS (+/- IL-7) every 3–4 days and spleens were analyzed
by flow cytometry after 10–24 days. (A-E) Shown are numbers of (A) splenocytes (Splen.), (B) CD11b+Gr1+
granulocytes (Gran.), (C) CD11c+MHC-II+ dendritic cells (DCs), (D) CD8+ and (E) CD8- DCs. Shown are
pooled data (±SEM) from 2 independent experiments with a total of 7–8 mice/group.
doi:10.1371/journal.pone.0159690.g003
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Fig 4. Host IL-7R signalingmodulates CD8+ T cell expansion and differentiation in response to
peptide vaccination and IL-7 therapy. (A-J) Rag-/- and Rag-/-IL-7R-/- mice were reconstituted with
CD8+CD90.1+ OT-I T cells and treated with SIINFEKL +/- rIL-7 as described in Fig 4. Three weeks after T cell
transfer (A, B) spleens and (C-J) peripheral blood were analyzed by flow cytometry. Shown are numbers of
(A) splenocytes and (B) splenic CD8+CD90.1+ OT-I T cells. After gating on OT-I T cells, relative frequencies
IL-7 Therapy and Host Cells
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cells determine the levels of PD-1 expression by CD8+ T cells. Hence, immunomodulation by
rIL-7 relies on complex interactions between IL-7R+ host and therapeutic CD8+ T cells.
IL-7R+ non-hematopoietic cells are crucial for CD8+ T cell expansion in
response to vaccination and rIL-7 therapy
Prolonged exposure to elevated levels of IL-7 down modulates il-7 gene activity in non-BM-
derived cells [4,12], which are the major source of IL-7 in vivo [20]. To determine whether
non-hematopoietic cells respond to rIL-7 therapy, IL-7 reporter mice expressing luciferase
under the control of the il-7 promoter [11] were treated with rIL-7. As a readout for il-7 gene
activity, bioluminescence intensities (BLI) were determined before and after rIL-7 treatment.
As shown in S2 Fig, rIL-7 administration reduced il-7 promoter activity significantly demon-
strating that IL-7-producing non-BM-derived cells indeed respond to rIL-7 therapy.
In order to study the relative contribution of IL-7R signaling in hematopoietic versus non-
hematopoietic host cells to rIL-7-induced CD8+ T cell responses, we generated bone marrow
(BM) chimeric mice. Lethally irradiated CD45.1+ Rag-/- mice received BM from CD45.1+
Rag-/- (R! R chimeras) or CD45.2+ Rag-/-IL-7R-/- mice (RR! R chimeras). Furthermore,
lethally irradiated CD45.2+ Rag-/-IL-7R-/- mice received BM from CD45.2+ Rag-/-IL-7R-/-
(RR! RR chimeras) or CD45.1+ Rag-/- mice (R! RR chimeras). Flow cytometric analysis of
CD45.1/.2-disparate RR! R and R! RR chimeras revealed that donor BM contributed to
the generation of around 97% of splenic CD11b+ cells (data not shown). BM-reconstituted
mice received OT-I cells, vaccination and rIL-7 therapy as described above. Three weeks after
adoptive T cell transfer, we first quantified splenic CD11b+ cells and DCs. To our surprise, IL-
7R expression by BM-derived cells was dispensable for CD11b+ cell expansion if non-BM-
derived cells expressed the IL-7R (Fig 5A; R! R vs RR! R chimeras). If, however, BM-
and non-BM-derived cells lacked the IL-7R, CD11b+ cell expansion was strongly impaired
(RR! RR). Only a partial recovery was observed if BM-derived cells produced the IL-7R (Fig
5A; R! RR) suggesting that IL-7R signaling in BM- and non-BM-derived cells synergize to
promote therapy-induced CD11b+ cell expansion. Similarly, the expansion of IL-7R-competent
and -deficient DCs was comparable in Rag-/- BM recipients (R! R vs RR! R). On the con-
trary, DC expansion was strongly impaired in RR! RR chimeras and only partially recovered
in R! RR chimeras (Fig 5B). Hence, IL-7R signaling in non-BM cells is crucial for therapy-
associated DC expansion. However, this appeared to be more important for CD8+ DCs than
for CD8- DCs (Fig 5C and 5D).
Similar to DCs, OT-I accumulation in the spleen was independent of IL-7R expression by
BM derived cells if non-BM-derived cells expressed the IL-7R (Fig 5E; R! R vs RR! R). In
accordance with Fig 4B, OT-I responses were least efficient in chimeras lacking the IL-7R on
BM-derived and non-BM-derived cells (Fig 5E; RR! RR). Importantly, IL-7R expression by
BM-derived cells alone was insufficient to fully recover OT-I accumulation (Fig 5E; R! RR).
IL-7 treatment is known to alter homing patterns of CD8+ T cells [36]. To exclude migra-
tion-related differences in splenic OT-I cell numbers, BM chimeras were reconstituted with
renilla luciferase-transgenic (ChRluctg) CD8+ OT-I T cells [27], vaccinated and treated with
(frequ.) of (C) CD62Lhi, (E) KLRG-1hi, (F) Ki67hi, (H) IFN-γhi, (I) TNF-αhi OT-I cells and relative MFIs for (D)
CD127, (Γ) Bcl-2 and (J) PD-1 were determined. (H, I) Cytokine production was measured after in vitro
stimulation of PBMCs with 1 μMSIINFEKL peptide in the presence of Rag-/- splenocytes, brefeldin A and
monensin for 6 hours. Relative (rel.) values were calculated as described in Fig 2. Bar diagrams show pooled
data (±SEM) from 3 independent experiments with a total of 15–18 mice/group. Histogram overlays show
representative results for individual mice. Dashed lines in overlays represent (C-G and J) FMO control
samples or (H, I) stained cells without prior SIINFEKL stimulation.
doi:10.1371/journal.pone.0159690.g004
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rIL-7. Six days later, whole-body BLI levels were determined to quantify relative OT-I cell
numbers in an unbiased, tissue-independent fashion. As shown in Fig 5F, ChRluctg OT-I were
similarly abundant in R! R and RR! R chimeras. On the contrary, their frequency was
strongly impaired in RR! RR chimeras and only partially recovered in R! RR chimeras.
Hence, these results confirm Fig 5E and further emphasize the importance of IL-7R+ non-BM
cells for rIL-7-induced CD8+ T cell expansion.
IL-7R+ non-BM cells modulate CD8+ TM differentiation in response to
vaccination and rIL-7 therapy
Having shown that non-BM cells promote the expansion of CD8+ T cells, we analyzed their
phenotype. Three weeks after adoptive transfer, OT-I cells isolated from the spleens of BM chi-
meras were analyzed by flow cytometry. In agreement with Fig 4E, KLRG-1hi OT-I cells were
more frequent in RR! RR than in R! R chimeras (Fig 6A) further emphasizing that TM dif-
ferentiation into KLRG-1hi cells is modulated by IL-7R+ host cells. These cells appear to be of
BM and non-BM origin as shown by the fact that R! RR chimeras contained most KLRG-1hi
OT-I cells. However, their numbers were reduced in RR! RR chimeras and lowest in R! R
and RR! R chimeras (Fig 6A).
The frequencies of CD62Lhi OT-I cells were identical in R! R and RR! RR chimeras sug-
gesting their host IL-7R-independence (Fig 6B). However, CD62Lhi OT-I cells were less abun-
dant in RR! R and R! RR (Fig 6B). This indicates that IL-7R+ BM- and non-BM-derived
cells are part of a complex network exerting opposing functions on CD62Lhi TM differentiation.
Highest levels of CD127 were found on OT-I cells from R! R and RR! R chimeras and
lowest on those from RR! RR chimeras (Fig 6C) demonstrating that IL-7R expression by
Fig 5. IL-7R signaling in non-hematopoietic host cells contributes to granulocyte, DC and CD8+ T cell
expansion in response to IL-7 therapy. Lethally irradiated CD45.1+ Rag-/- and CD45.2+ Rag-/-IL-7R-/- mice
were reconstituted with the indicated bone marrow (BM) cells (donor!recipient). After successful BM
reconstitution, BM chimeras received 1 x 106 CD8+ OT-I T cells. One day later, mice were vaccinated with
50 μg SIINFEKL. IL-7 treatment was done as described above. (A-E) Three weeks after T cell transfer,
recipient spleens were analyzed by flow cytometry and the numbers of the indicated cell types were
determined. Shown are pooled data (±SEM) of 3 independent experiments with a total of 10–17 mice/group.
(F) BM chimeras received 1 x 106 renilla luciferase-transgenic (ChRluctg) CD8+ OT-I T cells (OT-IChRluc) and
were treated with SIINFEKL and rIL-7 as described above. Six days after T cell transfer, mice were treated
with 100 μg colenterazine to determine bioluminescence intensities (BLI) as a readout for OT-I abundance
and distribution. Shown are pooled results (±SEM) of 2 independent experiments with a total of 5–10 mice/
group.
doi:10.1371/journal.pone.0159690.g005
IL-7 Therapy and Host Cells
PLOS ONE | DOI:10.1371/journal.pone.0159690 July 22, 2016 10 / 17
non-BM cells is a prerequisite for maximum CD127 expression by CD8+ T cells. If only BM-
derived cells expressed the IL-7R (R! RR) CD127 levels were significantly higher than in
RR! RR chimeras but still below those found on OT-I cells primed in RR! R chimeras (Fig
6C). Thus, IL-7R+ non-BM cells are major regulators of CD127 expression by OT-I cells.
The genes encoding Bcl-2 and CD8 are direct targets of IL-7 and other cytokines utilizing
the IL-2Rγc (CD132) for signal transduction [37]. CD127
lo OT-I cells from RR! RR chimeras
expressed highest levels of CD132, Bcl-2 and CD8 (Fig 6D–6F) suggesting that other
CD132-dependent cytokines than IL-7 caused the differentiation of CD127loCD132hiBcl-
2hiCD8hi TM cells in RR! RR chimeras. In contrast, R! R and RR! R chimeras rather con-
tained CD127hiCD132loBcl-2loCD8lo OT-I cells (Fig 6C–6F). However, if only BM-derived
cells expressed the IL-7R (R! RR) we observed an intermediate OT-I phenotype (Fig 6C–6G
and 6F).
In response to rIL-7 treatment PD-1 was downregulated only on OT-I cells primed in Rag-/-
mice but not on those primed in Rag-/-IL-7R-/- mice (Fig 4J). In agreement with this, PD-1
expression was most pronounced in RR! RR chimeras (Fig 6G). PD-1 levels were signifi-
cantly lower in both groups of chimeras expressing IL-7R on non-BM-derived cells and (R!
Fig 6. IL-7R signaling in non-hematopoietic cells regulates CD8+ T cell differentiation in response to
peptide vaccination and IL-7 therapy. (A-G) The indicated BM chimeras received CD8+ OT-I T cells and
were treated with SIINFEKL and rIL-7 as described above. Three weeks after T cell transfer, splenic CD8+
OT-I T cells were analyzed by flow cytometry. Bar diagrams show pooled results (±SEM) of 2–3 independent
experiments with a total of (A, B, C, E, G) 10–17 or (D) 4–10 mice/group. Histogram overlays show
representative results for individual mice. Grey-lined histograms represent FMO staining controls.
doi:10.1371/journal.pone.0159690.g006
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R and RR! R). In contrast, OT-I cells from R! RR chimeras showed an intermediate pheno-
type (Fig 6G) indicating that IL-7R+ non-BM-derived cells are major regulators of PD-1
expression by CD8+ T cells.
In summary, IL-7R+ host cells promoted the expansion of CD8+ TM cells in response to rIL-
7 therapy (Fig 4B–4J). Surprisingly, regulatory host cells were mainly of non-BM origin (Figs
5E, 5F and 6).
The combination of rIL-7 therapy and peptide vaccination impairs T cell-
dependent tumor rejection in Rag-/- mice
CD8+ CD62LhiKLRG-1loIFN-γhiPD-1lo TM cells are well suited to provide long-term protec-
tion against chronic infections and tumors [7,38,39]. Peptide vaccination and rIL-7 therapy
induced the generation of such TM cells in Rag
-/- mice (Fig 4B–4J), a process that was mainly
controlled by IL-7R+ non-hematopoietic cells (Figs 5E, 5F and 6). However, their therapeutic
potential remained unclear. To test this, Rag-/- mice were reconstituted with CD8+ OT-I T cells
and vaccinated with SIINFEKL one day later. Additionally, mice received rIL-7 or PBS accord-
ing to the scheme described above. To ensure appropriate OT-I expansion and differentiation,
mice were challenged with EG7 cells 21 days after adoptive T cell transfer. In untreated Rag-/-
control mice, EG7 tumors grew rapidly (Fig 7A). In contrast, 6/12 peptide-vaccinated Rag-/-
mice remained tumor free (Fig 7A). Surprisingly, however, only 2/12 Rag-/- mice rejected EG7
lymphomas after rIL-7 therapy (Fig 7A). Importantly, this was not due to impaired DC expan-
sion in rIL-7-treated Rag-/- mice (Fig 7C). Hence, the protective effect of peptide vaccination
was blunted by rIL-7.
Correlating with their comparably low frequency (Fig 4B) and KLRG-1hiIFN-γlo phenotype
(Fig 4E and 4H), SIINFEKL-induced TM cells rejected EG7 tumors only in 2/12 Rag
-/-IL-7R-/-
mice (Fig 7B). After rIL-7 therapy only 1/12 Rag-/-IL-7R-/- mice remained tumor free (Fig 7B).
In summary, the protective effect of peptide vaccination relied on host IL-7R signaling and was
blunted by rIL-7 therapy.
Discussion
The major goal of our study was to clarify whether and how host IL-7R signaling contributes to
rIL-7-driven anti-tumor CD8+ T cell responses. For this purpose, SIINFEKL-specific CD8+
Fig 7. The combination of rIL-7 therapy and peptide vaccination impairs T cell-dependent tumor
rejection in Rag-/- mice. (A) Rag-/- and (B) Rag-/-IL-7R-/- mice were reconstituted with 1 x 106 CD8+CD90.1+
OT-I T cells or were left untreated (+/- OT-I). One day later, OT-I-reconstituted mice were either vaccinated
with 50 μg SIINFEKL or received PBS (+/- Pep). rIL-7 or PBS (+/- IL-7) were injected every 3–4 days for 19
days starting one day before T cell transfer. Mice were challenged s.c. with 1 x 106 EG7 tumor cells three
weeks after T cell transfer. Mice with tumors larger than 250 mm3 were scored as tumor positive. Shown are
pooled data from 2 independent experiments with a total of 12–13 T cell reconstituted mice. Primary tumor
growth was analyzed in untreated Rag-/- and Rag-/-IL-7R-/- mice (n = 3). Statistical significance was calculated
using the log-rank test. (C) The numbers of splenic DCs were determined in tumor-bearing mice 28–37 days
after tumor challenge. Pooled data (±SEM) from 2 independent experiments with a total of 6–11 mice/group
are shown. Statistical significance was calculated using the Mann-Whitney test.
doi:10.1371/journal.pone.0159690.g007
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OT-I cells were transferred into Rag-/- and Rag-/-IL-7R-/- mice, which were then treated with
rIL-7. As shown in Fig 1A, OT-I-reconstituted Rag-/- mice receiving IL-7 therapy rejected
SIINFEKL-expressing EG7 lymphoma cells. This was not the case for Rag-/-IL-7R-/- mice dem-
onstrating that the success of rIL-7 therapy is dependent on host IL-7R expression in our
experimental system. However, CD8+ T cell expansion and differentiation were largely inde-
pendent of host IL-7R signaling. Irrespective of host IL-7R expression nearly identical numbers
of OT-I cells were recovered from spleens after rIL-7 treatment. Similarly, the differentiation of
CD8+ TM with a CD127
hiBcl-2hiCD62LhiKLRG-1loIFN-γhi phenotype was induced in rIL-
7-treated Rag-/- and Rag-/-IL-7R-/- mice. Hence, our data show that rIL-7-induced CD8+ T cell
expansion and subsequent TM differentiation are not affected by host IL-7R expression and
related differences in IL-7 availability (Fig 1D). In agreement with previous studies [21], the
beneficial effects of rIL-7 on CD8+ T cell function, differentiation and survival appear to result
mainly from IL-7R signaling in CD8+ T cells. Nevertheless, it is important to stress that effec-
tive CD8+ T cell expansion and differentiation do not necessarily correlate with tumor rejec-
tion. This conclusion is supported by the fact that rIL-7-induced OT-I expansion and
subsequent TM differentiation occurred efficiently in Rag
-/-IL-7R-/- mice while tumor rejection
failed. This finding emphasizes the importance of IL-7-responsive host cells for rIL-7-assisted
ATT in our model system.
Dendritic cells promote CD8+ T cell responses under lymphopenic conditions [40], cross-
present tumor-derived antigens [41] and expand in response to rIL-7 treatment [24], which
promotes T-DC interactions [42]. Additionally, rIL-7 stimulates myelopoiesis and the subse-
quent accumulation of CD11b+ cells [25], which can cross-present tumor antigens and pro-
mote CD8+ T cell-mediated tumor rejection [43]. After rIL-7 treatment, DCs and granulocytes
accumulated only in IL-7R-competent mice. However, this accumulation was not required for
expansion and functional maturation of OT-I cells but correlated positively with tumor rejec-
tion. This suggests that rIL-7-expanded DCs and granulocytes support CD8+ T cell responses
in the late effector phase rather than in the early phase after adoptive transfer.
IL-7R signaling in combination with TCR stimulation boosts CD8+ T cell responses in mul-
tiple experimental systems. TCR signal strength and the timing of IL-7R signaling appear to be
important to achieve optimal IL-7 effects [44]. To generate maximum CD8+ T cell responses,
we reconstituted Rag-/- and Rag-/-IL-7R-/- mice with OT-I cells and vaccinated them with SIIN-
FEKL. Unlike after rIL-7 treatment alone, host IL-7R signaling was crucial for maximum OT-I
expansion in response to vaccination and rIL-7. Additionally, OT-I cells up-regulated CD127
and down-modulated PD-1 in a host-IL-7R-dependent fashion. This was not the case for all
other markers tested. The host-dependent modulation of CD8+ T cell differentiation was con-
firmed in BM chimeras. Surprisingly, we identified IL-7R+ radio-resistant host cells as major
regulators of CD8+ T cell expansion and differentiation. For maximum levels of CD127 expres-
sion and restriction of KLRG-1, CD132, Bcl-2, CD8, and PD-1, IL-7R expression by radio-
resistant host cells was sufficient. CD127 expression is modulated by multiple intracellular sig-
naling events in T cells. Whether non-BM-derived host cells affect these or other signaling
pathways remains open.
Besides OT-I expansion and differentiation, IL-7R+ non-BM-derived cells also controlled
granulocyte and DC expansion. Even if donor BM was devoid of the IL-7R, its expression by
radio-resistant cells supported the expansion of CD11b+ cells and DCs. However, IL-7R
expression by BM-derived cells was largely sufficient to rescue the expansion of CD11b+ cells
and CD8- DCs. Surprisingly, this was not the case for CD8+ DCs. Their accumulation
depended more on IL-7R expression by non-BM- than by BM-derived cells. Together, we dem-
onstrate that IL-7R signaling in BM- and non-BM-derived cells contributes to rIL-7-driven DC
expansion. This might help to reconcile apparently conflicting results regarding the relative
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importance of cell autonomous IL-7R signaling for DC generation obtained in different experi-
mental systems [24,45].
Fibroblastic reticular cells (FRCs) and lymphoid endothelial cells (LECs) are major sources
of IL-7 in secondary lymphoid organs [46]. Furthermore, other cells of non-BM origin such as
intestinal epithelial cells (IECs) [47], keratinocytes [48], hepatocytes [49] and fibroblasts [50]
were shown to produce IL-7 in vivo. The maintenance of CD8+ T cell homeostasis requires IL-
7R signaling in CD8+ T cells which is triggered by IL-7 from non-BM derived cells [20]. How-
ever, only little is known about the consequences of IL-7R signaling in non-BM-derived cells
and subsequent immune modulation [51]. As we have shown in S2 Fig, the application of rIL-7
leads to the systemic down-modulation of il-7 gene activity supporting previous reports dem-
onstrating that il-7 gene activity is regulated in an IL-7-mediated negative feedback loop [4,12].
Given that IL-7R signaling modulates gene expression profiles in multiple non-BM-derived
cell types [4,12,26], long-term rIL-7 therapy would not only affect immune cell but also non-
immune cell homeostasis. For instance, prolonged IL-7 overabundance promotes IEC expan-
sion, survival and subsequent alterations in intestinal physiology [12]. Since many cell types of
non-BM-derived origin can express the IL-7R [31], the local down regulation of endogenous
IL-7 production and alterations in tissue homeostasis might be as yet underestimated side
effects of rIL-7 therapy. Whether i) non-BM-derived cells located in the tumor stroma and/or
other tissues are the main targets of rIL-7, and ii) whether rIL-7 signaling in such cells pro-
motes or suppresses rIL-7-assisted ATT remains to be shown.
IL-7R+ host cells appear to promote antigen-dependent CD8+ T cell function also in an IL-
7-independent fashion. For example, successful peptide vaccination and subsequent tumor
rejection, in the absence of rIL-7 treatment, strictly required host IL-7R expression (Fig 7A and
7B). Importantly, however, peptide vaccination blocked the therapeutic effect of rIL-7 (Figs 1A
and 7A) in Rag-/- mice although IL-7R-dependent DC expansion was normal (Fig 7C). It has
been reported that TCR signaling can interfere with the beneficial effects of IL-7 on T cells
[52]. Hence, impaired tumor rejection in rIL-7-treated, peptide vaccinated Rag-/- mice might
have been a result of altered T cell rather than host cell function.
In summary, our data provide evidence for the complex interplay between IL-7R+ host and
CD8+ T cells in the course of anti-tumor CD8+ T cell responses. While productive host-CD8+
T cell interactions can be promoted by rIL-7 therapy, the inappropriate combination with
other immune stimuli can cause adverse effects.
Supporting Information
S1 Fig. Lymphopenia-induced T cell proliferation (LIP) is independent of host IL-7R sig-
naling. (A, B) Rag-/-, Rag-/-IL-7R-/- and WT mice were reconstituted with 1 x 106 CD8+-
CD90.1+ OT-I T cells. Spleens were analyzed by flow cytometry 21–27 days later. Shown are
(A) relative fluorescence intensities for CD44 on CD8+CD90.1+ OT-I T cells. (B) Cell numbers
were normalized to the mean values determined in treated Rag-/- mice and are shown as rela-
tive (rel.) values. Data (±SEM) from 3 independent experiments with a total of 9–19 mice/
group are shown.
(EPS)
S2 Fig. IL-7 administration decreases host il-7 expression. (A, B) IL- representative mouse
before (0h) and 24 hours (24h) after IL-7 treatment are shown. (B) BLI levels measured at 24h
were calculated in relation to those determined before treatment and relative BLI (rel. BLI) val-
ues were calculated. Shown are pooled data (± SEM) of 2 experiments with a total of 6 mice.
Statistical analysis was performed using Wilcoxon matched-pairs signed rank test.
(EPS)
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